KR100682549B1 - Sesamol derivatives and process for preparing the same - Google Patents

Sesamol derivatives and process for preparing the same Download PDF

Info

Publication number
KR100682549B1
KR100682549B1 KR1020050067815A KR20050067815A KR100682549B1 KR 100682549 B1 KR100682549 B1 KR 100682549B1 KR 1020050067815 A KR1020050067815 A KR 1020050067815A KR 20050067815 A KR20050067815 A KR 20050067815A KR 100682549 B1 KR100682549 B1 KR 100682549B1
Authority
KR
South Korea
Prior art keywords
sesamol
acid
derivative
derivatives
formula
Prior art date
Application number
KR1020050067815A
Other languages
Korean (ko)
Other versions
KR20070013482A (en
Inventor
유재원
노호식
김덕희
장이섭
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to KR1020050067815A priority Critical patent/KR100682549B1/en
Publication of KR20070013482A publication Critical patent/KR20070013482A/en
Application granted granted Critical
Publication of KR100682549B1 publication Critical patent/KR100682549B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 하기 화학식 1로 표시되는 세사몰 유도체 및 그의 제조방법에 관한 것이다. 보다 상세하게는, 상기 세사몰 유도체는 세사몰과 아다만탄올을 1 : 1.0~1.3의 당량비로 산조건에서 반응시킨 후, 극성용매에서 재결정하여 제조한다. The present invention relates to sesamol derivatives represented by the following formula (1) and a method for preparing the same. More specifically, the sesamol derivative is prepared by reacting sesamol and adamantanol in an acid condition at an equivalent ratio of 1: 1.0 to 1.3, and recrystallization in a polar solvent.

Figure 112005040755381-pat00001
Figure 112005040755381-pat00001

상기 유도체는 강력한 항산화력을 갖는 물질로서 유해 활성산소에 의하여 손상된 피부의 회복 및 예방에 쓰일 수 있고, 생체막의 노화를 방지할 수 있으며, 불포화지방산 및 그 유도체의 과산화물 생성을 억제할 수 있다. The derivative is a substance having a strong antioxidant power can be used for the recovery and prevention of skin damaged by harmful free radicals, can prevent the aging of the biofilm, and can inhibit the production of unsaturated fatty acids and peroxides thereof.

세사몰유도체 * 항산화 * 과산화 * 아다만탄올 * 세사몰 Sesamol Derivative * Antioxidant * Peroxide * Adamantanol * Sesamol

Description

세사몰 유도체 및 그의 제조방법{Sesamol derivatives and process for preparing the same}Sesamol derivatives and process for preparing the same {Sesamol derivatives and process for preparing the same}

본 발명은 하기 화학식 1로 표시되는 세사몰 유도체 및 그의 제조방법에 관한 것이다. 보다 상세하게는, 상기 세사몰 유도체는 세사몰과 아다만탄올을 1 : 1.0~1.3의 당량비로 산조건에서 반응시킨 후, 극성용매에서 재결정하여 제조한다. The present invention relates to sesamol derivatives represented by the following formula (1) and a method for preparing the same. More specifically, the sesamol derivative is prepared by reacting sesamol and adamantanol in an acid condition at an equivalent ratio of 1: 1.0 to 1.3, and recrystallization in a polar solvent.

[화학식 1][Formula 1]

Figure 112005040755381-pat00002
Figure 112005040755381-pat00002

화장료의 기능은 피부 및 모발을 청결하게 하고 미화하며, 건강하게 하는 것이다. 특히, 이중에서 항산화 활성에 의해 피부에 잔주름의 생성을 방지하고자 하는 연구가 많이 이루어지고 있으며, 많은 물질들이 개발되어 사용되고 있다. 이러한 물질로는 아스코르빈산, 토코페롤 등의 비타민류, 각종 동식물에서 추출한 플라보노이드 등이 알려져 있다. The function of cosmetics is to cleanse, beautify and health the skin and hair. In particular, many studies have been made to prevent the formation of fine wrinkles on the skin due to antioxidant activity, and many substances have been developed and used. As such substances, vitamins such as ascorbic acid and tocopherol, flavonoids extracted from various animals and plants are known.

천연에 존재하는 또 하나의 강력한 항 산화물질인 세사몰(Sesamol)은 참기름의 주성분이다. 참기름은 다른 기름에 비해서 산폐가 잘 일어나지 않는 것으로 알려져 있으며, 이와 같은 현상에 대한 이유는 세사몰의 항산화 효능에 의한 것이다. 그러나, 세사몰 역시 다양한 항산화 효능에도 불구하고 다른 천연 항산화제들처럼 제형에 적용시 불안정해지는 문제점을 가지고 있다. Sesamol, another powerful antioxidant in nature, is the main component of sesame oil. Sesame oil is known to be less likely to produce acid than other oils, the reason for this phenomenon is due to the antioxidant efficacy of sesamol. However, sesamol also has a problem of being unstable when applied to the formulation, like other natural antioxidants, despite a variety of antioxidant efficacy.

이에, 본 발명자들은 상기한 문제점을 해결하기 위해 안정성이 향상된 세사몰 유도체를 개발하고자 연구하였고, 그 결과 아다만탄기를 세사몰에 직접적으로 도입함으로써 세사몰의 항산화 효능이 증대되고 안정성이 향상되는 것을 발견하고, 본 발명을 완성하였다. Accordingly, the present inventors have studied to develop sesamol derivatives having improved stability to solve the above problems, and as a result, the antioxidant efficacy of sesamol is increased and stability is improved by introducing the adamantane group directly into sesamol. The present invention was completed.

따라서, 본 발명의 목적은 아다만탄기를 세사몰에 직접적으로 도입함으로써 항산화 효능이 증대되고 안정성이 향상된 세사몰 유도체를 제공하는 것이다. Accordingly, it is an object of the present invention to provide sesamol derivatives having improved antioxidant efficacy and improved stability by introducing adamantane groups directly into sesamol.

또한, 본 발명의 다른 목적은 상기 세사몰 유도체의 제조방법을 제공하는 것이다. Another object of the present invention is to provide a method for preparing the sesamol derivative.

상기한 목적을 달성하기 위하여, 본 발명에서는 하기 화학식 1로 표현되는 세사몰의 유도체를 제공하는 것을 특징으로 한다. In order to achieve the above object, the present invention is characterized by providing a derivative of sesamol represented by the following formula (1).

[화학식 1][Formula 1]

Figure 112005040755381-pat00003
Figure 112005040755381-pat00003

이하, 본 발명을 보다 상세히 설명한다. Hereinafter, the present invention will be described in more detail.

본 발명에 의한 세사몰 유도체는 세사몰과 아다만탄올을 1 :1.0~ 1.3의 당량비로 산조건에서 반응시킨 후, 극성용매에서 재결정하여 제조한다. Sesamol derivatives according to the present invention are prepared by reacting sesamol and adamantanol in acid conditions at an equivalent ratio of 1: 1.0 to 1.3, and recrystallization in a polar solvent.

본 발명에 의한 세사몰 유도체의 제조방법은 하기 반응식 1로 도식화될 수 있다;The method for preparing sesamol derivatives according to the present invention may be represented by Scheme 1 below;

Figure 112005040755381-pat00004
Figure 112005040755381-pat00004

상기 반응식 1에서 세사몰과 아다만탄올 1:1.0~1.3의 당량비로 산조건하에서 반응시키는 것이 바람직하다. 이때, 당량비가 1:1.0 미만이면 목적하는 생성물을 얻을 수 없고, 1: 1.3를 초과하면 목적하는 생성물 이외에 부산물 및 미반응물의 양이 증가하게 된다. In Scheme 1, it is preferable to react the sesamol and adamantanol under an equivalence ratio of 1: 1.0 to 1.3 under acidic conditions. At this time, if the equivalent ratio is less than 1: 1.0, the desired product cannot be obtained. If the ratio exceeds 1: 1.3, the amount of by-products and unreacted substances other than the desired product is increased.

또한, 반응온도 및 반응시간은 10~50℃의 온도에서 1~2시간 동안 반응시키는 것이 바람직하다. 10℃ 미만에서는 반응속도가 너무 느려서 반응시간이 길어지고 미반응물의 함량이 증가되어 반응 수율이 낮아지는 단점이 있으며, 50℃ 초과에서는 부산물이 과량 생성되는 단점이 있다. In addition, the reaction temperature and the reaction time is preferably reacted for 1 to 2 hours at a temperature of 10 ~ 50 ℃. If it is less than 10 ℃ has a disadvantage that the reaction time is too slow, the reaction time is long and the content of unreacted material is increased, the reaction yield is lowered, the excess by-products are generated above 50 ℃.

또한, 상기 반응식 1에서 사용되는 산으로는 염산, 질산, 황산, p-톨루엔술폰산, 벤젠술폰산, 아세트산, 트리클로로아세트산, 트리플로로아세트산 등을 사용할 수 있으며, 바람직하게는 황산, 트리클로로아세트산, 트리플로로아세트산을 사용하는 것이다. In addition, the acid used in Scheme 1 may be hydrochloric acid, nitric acid, sulfuric acid, p-toluenesulfonic acid, benzenesulfonic acid, acetic acid, trichloroacetic acid, trichloroacetic acid, and the like, preferably sulfuric acid, trichloroacetic acid, It is to use trifluoroacetic acid.

또한, 상기 반응식 1에서 사용되는 용매로는 디클로로메탄, 테트라히드로퓨란, 초산에틸, 아세토니트릴, 클로로포름, 에틸에테르, 트리클로로 에틸렌, 벤젠, 톨루엔 등과 같은 유기용매를 사용할 수 있으며, 사용되는 산이 액체인 경우에는 산을 용매로 사용할 수도 있다. 바람직하게는, 톨루엔을 사용하거나 트리클로로아세트산 및 트리플로로아세트산을 용매 겸 산으로 사용하는 것이다. In addition, as the solvent used in Scheme 1, an organic solvent such as dichloromethane, tetrahydrofuran, ethyl acetate, acetonitrile, chloroform, ethyl ether, trichloroethylene, benzene, toluene, etc. may be used, and the acid used may be a liquid. In this case, acid may be used as a solvent. Preferably, toluene is used or trichloroacetic acid and trichloroacetic acid are used as the solvent and the acid.

상기 반응이 종료되면 극성용매를 사용하여 재결정을 하며, 여기에서 사용되는 극성 유기용매로는 특별히 한정되지는 않지만, 예를 들면, 메탄올, 에탄올, 이소프로판올, 아세톤, 아세토나이트릴, 물 등이 있다.When the reaction is completed, recrystallization is performed using a polar solvent, and the polar organic solvent used herein is not particularly limited, but for example, methanol, ethanol, isopropanol, acetone, acetonitrile, water and the like.

본 발명에 의한 세사몰 유도체는 세사몰을 단독으로 사용하는 경우보다 향상된 항산화활성을 나타낸다. Sesamol derivatives according to the present invention exhibit improved antioxidant activity than sesamol alone.

본 발명의 세사몰 유도체는 화장료 및 의약품 조성물에 적용될 수 있을 것이다. 한편, 의약용으로 사용될 경우, 당업자라면 환자의 상태, 병의 정도에 따라 사용량을 용이하게 적절히 제한할 수 있다. Sesamol derivatives of the present invention may be applied to cosmetic and pharmaceutical compositions. On the other hand, when used in medicine, those skilled in the art can easily appropriately limit the amount of use according to the condition of the patient, the degree of illness.

이하 실시예 및 시험예를 들어 본 발명을 보다 상세하게 설명하지만, 본 발명이 이들 예로만 한정되는 것은 아니다.Although an Example and a test example are given to the following and this invention is demonstrated in more detail, this invention is not limited only to these examples.

[실시예 1] 3,4-메틸렌디옥시-6-아다만틸페놀Example 1 3,4-methylenedioxy-6-adamantylphenol

세사몰 1.38g(1.0eq)과 아다만탄올 1.52g(1.0eq)을 트리플로로아세트산 5㎖에 가한 다음, 온도를 40℃ 정도로 가온하여 1시간 정도 교반하였다. 반응이 종료된 반응액에 메탄올이나 물 50㎖를 가한 후, 30분 정도 교반하여 준다. 결정화가 되면 여과한 다음, 진공건조하여 생성물인 3,4-메틸렌디옥시-6-아다만틸페놀 2.2g을 고체상으로 얻었다.1.38 g (1.0 eq) of sesamol and 1.52 g (1.0 eq) of adamantanol were added to 5 ml of trichloroacetic acid, and the temperature was warmed to about 40 ° C. and stirred for about 1 hour. 50 ml of methanol or water is added to the reaction solution after the reaction is completed, followed by stirring for about 30 minutes. After crystallization, the mixture was filtered and then dried in vacuo to yield 2.2 g of 3,4-methylenedioxy-6-adamantylphenol as a solid.

1H-NMR(CDCl3) : δ(ppm) = 1.78(6H), 2.07(9H), 4.76(s, 1H), 5.91(s, 2H), 6.21(s, 1H), 6.52(s, 1H)1 H-NMR (CDCl 3): δ (ppm) = 1.78 (6H), 2.07 (9H), 4.76 (s, 1H), 5.91 (s, 2H), 6.21 (s, 1H), 6.52 (s, 1H)

[시험예1] HaCat 모델을 이용한 항산화 효과 측정 Test Example 1 Measurement of Antioxidant Effect Using HaCat Model

인간 각질 세포 HaCat 세포주를 60mm 디쉬당 1.0 X 106개로 분주하고 페니실린/스트렙토마이신이 첨가된 DMEM(FBS 10%) 배지를 사용하여 37℃, 5% CO2 조건에서 1일간 배양하였다. 다음, 세사몰과 상기 실시예 1의 세사몰 유도체를 10-4몰 농도로 처리하였고, 양성 대조군으로 사용한 토코페롤도 동일한 농도로 24시간 동안 처리하였다. 다음날 위의 조성물과 동시에 4mM의 t-BHT(t-butyl hydroperoxide)를 처리 한 후, 37℃, 5% CO2 조건에서 4시간 동안 배양 한 후 세포를 수득하였다. 상기 세포는 냉동/해동 공정을 반복하는 방법으로 용해하였으며, 이하의 시험은 분석 키트에 나와 있는 방법에 준하여 시행하였다. Human keratinocytes HaCat cell lines were aliquoted at 1.0 × 10 6 per 60 mm dish and incubated for one day at 37 ° C., 5% CO 2 conditions using DMEM (FBS 10%) medium with penicillin / streptomycin. Next, sesamol and the sesamol derivative of Example 1 were treated at a concentration of 10 −4 mole, and tocopherol used as a positive control was also treated at the same concentration for 24 hours. The next day, after treatment with 4mM of t-BHT (t-butyl hydroperoxide) simultaneously with the above composition, cells were obtained after incubation for 4 hours at 37 ℃, 5% CO 2 conditions. The cells were lysed by repeating the freezing / thawing process, and the following test was performed according to the method described in the assay kit.

즉, 본 발명에서는 칼바이오켐 지질 과산화 분석 키트를 시약으로 사용하였고, 말론알데히드 및 4-히드록시 알케날과 같은 장쇄 불포화 지방산과 연관된 에스테르 과산화물이 상기 시약과 반응하여 586nm에서 안정한 화합물을 형성하는 원리를 이용하여 지질 과산화를 측정하였다. 비처리군을 100으로 하여 대비한 결과를 하기 표 1에 나타내었다. That is, in the present invention, Calbiochem lipid peroxidation assay kit was used as a reagent, and ester peroxides associated with long-chain unsaturated fatty acids such as malonaldehyde and 4-hydroxy alkenal react with the reagent to form a stable compound at 586 nm. Lipid peroxidation was measured using. The results of the non-treated group as 100 are shown in Table 1 below.

화합물compound MDE* MDE * 대조군Control 100100 t-BHTt-BHT 320320 토코페롤Tocopherol 270270 세사몰Sesa Mall 250250 실시예 1Example 1 230230 * MDE :지질 과산화 생성물인 말론디알데히드(Malondialdehyde)를 의미. * MDE: Refers to malondialdehyde, a lipid peroxide product.

상기 표 1에서 알 수 있는 바와 같이, 본 발명에 의한 실시예 1의 3,4-메틸렌디옥시-6-아다만틸페놀은 양성 대조군으로 사용한 토코페롤 및 세사몰보다 우수한 지질 과산화 억제효과를 나타냄을 확인하였다. As can be seen in Table 1, the 3,4-methylenedioxy-6-adamantylphenol of Example 1 according to the present invention showed a superior lipid peroxidation inhibitory effect than tocopherol and sesamol used as a positive control Confirmed.

[시험예2] DPPH법에 의한 항산화 효과 측정Test Example 2 Measurement of Antioxidant Effect by DPPH Method

항산화 효과 측정 방법은 대한민국 특허 출원 제 10-2002-0027050호에 의한 방법으로 실험하였다. 구체적으로, 측정 방법은 1,1-디페닐-2-피크릴-히드라질 (1,1-diphenyl- 2-picryl-hydrazyl,DPPH) 방법으로서, 이때 시약은 미국 시그마社 (St.Louis,MO,U.S.A)로부터 구입하여 사용하였다. 상기 시약은 비교적 안정한 자유 라디칼로 존재하기 때문에 자유 라디칼 소거 작용을 확인하는 과정에서 일차적으로 시험관적인 방법(in Vitro)으로 사용되고 있다. DPPH 자유 라디칼 소거 활성의 측정에 사용되는 토코페롤, 세사몰 및 상기 실시예 1을 500㎍/㎖, 100㎍/㎖, 20㎍/㎖, 4㎍/㎖, 0.8㎍/㎖의 농도별로 96 웰 플레이트에 각각 넣고, 여기에 100M 에탄올 용액으로 제조된 DPPH를 첨가하여 용액의 총 부피가 200㎕가 되게 하였다. 이것을 37℃에서 30분 간 방치한 후 520nm ELISA reader로 흡광도를 측정하였다. 자유 라디칼 소거 활성(%)은 다음의 수학식 1로 산출하였으며, 50%의 라디칼 소거능을 보이는 농도(IC50)를 계산하였다. 그 결과를 하기 표 2에 나타내었다.Antioxidant effect was measured by the method according to Korean Patent Application No. 10-2002-0027050. Specifically, the measuring method is 1,1-diphenyl-2-picryl-hydrazyl (1,1-diphenyl-2-picryl-hydrazyl, DPPH) method, wherein the reagent is US Sigma (St. Louis, MO , USA). The reagent is used as a primary in vitro methods (in Vitro) In the process of determining the free-radical scavenging activity due to the presence of a relatively stable free radicals. Tocopherol, sesamol and Example 1, which are used for the measurement of DPPH free radical scavenging activity, and 96-well plates by concentrations of 500 μg / ml, 100 μg / ml, 20 μg / ml, 4 μg / ml and 0.8 μg / ml In each, and added DPPH made of 100M ethanol solution to make the total volume of solution 200µl. After leaving it at 37 ° C. for 30 minutes, absorbance was measured using a 520 nm ELISA reader. Free radical scavenging activity (%) was calculated by the following equation (1), and the concentration (IC 50) showing a radical scavenging ability of 50% was calculated. The results are shown in Table 2 below.

<수학식 1><Equation 1>

Figure 112005040755381-pat00005
Figure 112005040755381-pat00005

A: 시료를 처리하지 않은 대조군 웰의 흡광도A: Absorbance of control wells without sample

B: 시료를 처리한 실험군 웰의 흡광도 B: Absorbance of Experimental Wells Treated with Samples

화합물compound 라디칼소거능(IC50)㎍/㎖Radical scavenging ability (IC50) µg / ml 토코페롤Tocopherol -- 세사몰Sesa Mall 13.213.2 실시예 1Example 1 10.210.2

상기 표 2에서 알 수 있는 바와 같이, 본 발명의 실시예 1의 3,4-메틸렌디옥시- 6-아다만틸페놀은 양성 대조군으로 사용한 토코페롤, 세사몰보다 우수한 라디칼 소거 효과를 나타냄을 확인하였다. As can be seen in Table 2, it was confirmed that the 3,4-methylenedioxy-6-adamantylphenol of Example 1 of the present invention showed an excellent radical scavenging effect than tocopherol and sesamol used as a positive control. .

[시험예 3] 변색 비교 실험Test Example 3 Discoloration Comparison Experiment

세사몰과 상기 실시예 1의 세사몰유도체를 비히클(디메틸포름알데히드:에탄올:물= 5:3:2)에 녹인 다음, 40℃ 항온실에서 보관하면서 변색 정도를 육안으로 관찰하고 하기 기준으로 평가하였다. 그 결과를 하기 표 3에 나타내었다. The sesamol and the sesamol derivative of Example 1 were dissolved in a vehicle (dimethylformaldehyde: ethanol: water = 5: 3: 2), and then visually observed for discoloration while being stored at 40 ° C. in a room temperature and evaluated based on the following criteria. It was. The results are shown in Table 3 below.

<평가기준><Evaluation Criteria>

⊙ : 변색 거의 없음         ⊙ almost no discoloration

O : 엷은 노란색으로 변색됨         O: discolored to pale yellow

△ : 진한 노란색으로 변색됨         △: discolored to dark yellow

X : 짙은 갈색으로 변색됨         X: discolored to dark brown

화합물compound 30일30 days 60일60 days 90일90 days 세사몰Sesa Mall X X X X 실시예 1Example 1 O O

상기 표 3에서 알 수 있는 바와 같이, 본 발명에 의한 실시예 1의 3,4-메틸렌디옥시- 6-아다만틸페놀은 세사몰에 비하여 변색의 문제점이 개선됨을 확인하였다. As can be seen in Table 3, the 3,4-methylenedioxy-6-adamantylphenol of Example 1 according to the present invention was confirmed to improve the problem of discoloration compared to sesamol.

본 발명에 따른 세사몰 유도체를 피부 외용제 조성물에 사용될 수 있는데, 그 제형에 있어서 특별히 한정되는 바가 없다. 예를 들면, 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일, 바디에센스, 메이컵 베이스, 파운데이션, 염모제, 샴푸, 린스 또는 바디 세정제 등의 화장료 조성물 또는 연고, 겔, 크림, 패취 또는 분무제 등의 의약용 조성물로 제형화될 수 있다. 이들 각 제형은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 발명자에 의해 용이하게 선정될 수 있다. Sesamol derivatives according to the present invention can be used in the external preparation composition for the skin, which is not particularly limited in the formulation. For example, supple cosmetics, astringent cosmetics, nourishing cosmetics, nourishing cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, body It may be formulated into a cosmetic composition such as an essence, a makeup base, a foundation, a hair dye, a shampoo, a rinse or a body cleanser, or a pharmaceutical composition such as an ointment, a gel, a cream, a patch or a spray. Each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by the inventors.

[제형예 1] 영양화장수(밀크로션) 제조 Formulation Example 1 Preparation of Nutritious Cosmetic Water (Milk Lotion)

상기 실시예 1에서 제조한 세사몰 유도체들을 함유하는 영양화장수를 제조하였다.Nutrients containing the sesamol derivatives prepared in Example 1 was prepared.

성분ingredient 함량(중량%)Content (% by weight) 1. 정제수1. Purified water To 100To 100 2. 글리세린2. Glycerin 8.08.0 3. 부틸렌글리콜3. Butylene Glycol 4.04.0 4. 히아루론산 추출물4. Hyaluronic Acid Extract 5.05.0 5. 베타글루칸5. Beta Glucan 7.07.0 6. 카보머6. Carbomer 0.10.1 7. 세사몰 유도체7. Sesamol Derivatives 적량Quantity 8. 카프릴릭 카프릭 트리글리세라이드8. Caprylic Capric Triglycerides 8.08.0 9. 스쿠알란9. Squalane 5.05.0 10. 세테아릴 글루코사이드10. Cetearyl Glucoside 1.51.5 11. 소르비탄 스테아레이트11.Sorbitan Stearate 0.40.4 12. 세테아릴 알코올12. Cetearyl Alcohol 1.01.0 13. 방부제13. Preservative 적량Quantity 14. 향14. Incense 적량Quantity 15. 색소15. Coloring 적량Quantity 16. 트리에탄올아민16. Triethanolamine 0.10.1

[제형예 2] 영양크림의 제조 Formulation Example 2 Preparation of Nutritional Cream

상기 실시예 1에서 제조한 세사몰 유도체들을 함유하는 영양크림을 제조하였다. Nutritional cream containing sesamol derivatives prepared in Example 1 was prepared.

성분ingredient 함량(중량%)Content (% by weight) 1. 정제수1. Purified water To 100To 100 2. 글리세린2. Glycerin 3.03.0 3. 부틸렌글리콜3. Butylene Glycol 3.03.0 4. 유동파라핀4. Liquid paraffin 7.07.0 5. 베타글루칸5. Beta Glucan 7.07.0 6. 카보머6. Carbomer 0.10.1 7. 세사몰 유도체7. Sesamol Derivatives 적량Quantity 8. 카프릴릭 카프릭 트리글리세라이드8. Caprylic Capric Triglycerides 3.03.0 9. 스쿠알란9. Squalane 5.05.0 10. 세테아릴 글루코사이드10. Cetearyl Glucoside 1.51.5 11. 소르비탄 스테아레이트11.Sorbitan Stearate 0.40.4 12. 폴리솔베이트12. Polysorbate 1.21.2 13. 방부제13. Preservative 적량Quantity 14. 향14. Incense 적량Quantity 15. 색소15. Coloring 적량Quantity 16. 트리에탄올아민16. Triethanolamine 0.10.1

[제형예 3] 맛사지 크림의 제조 Formulation Example 3 Preparation of Massage Cream

상기 실시예 1에서 제조한 세사몰 유도체들을 함유하는 맛사지 크림을 제조하였다. A massage cream containing sesamol derivatives prepared in Example 1 was prepared.

성분ingredient 함량(중량%)Content (% by weight) 1. 정제수1. Purified water To 100To 100 2. 글리세린2. Glycerin 8.08.0 3. 부틸렌글리콜3. Butylene Glycol 4.04.0 4. 유동파라핀4. Liquid paraffin 45.045.0 5. 베타글루칸5. Beta Glucan 7.07.0 6. 카보머6. Carbomer 0.10.1 7. 세사몰 유도체7. Sesamol Derivatives 적량Quantity 8. 카프릴릭 카프릭 트리글리세라이드8. Caprylic Capric Triglycerides 3.03.0 9. 밀랍9. Beeswax 4.04.0 10. 세테아릴 글루코사이드10. Cetearyl Glucoside 1.51.5 11. 세스퀴 올레인산 소르비탄11.Sesqui oleic acid sorbitan 0.90.9 12. 바세린12. Vaseline 3.03.0 13. 방부제13. Preservative 적량Quantity 14. 향14. Incense 적량Quantity 15. 색소15. Coloring 적량Quantity 16. 파라핀16. Paraffin 1.51.5

[제형예 4] 연고의 제조 Formulation Example 4 Preparation of Ointment

상기 실시예 1에서 제조한 세사몰 유도체들을 함유하는 연고를 제조하였다. An ointment containing the sesamol derivatives prepared in Example 1 was prepared.

성분ingredient 함량(중량%)Content (% by weight) 1. 정제수1. Purified water To 100To 100 2. 글리세린2. Glycerin 8.08.0 3. 부틸렌글리콜3. Butylene Glycol 4.04.0 4. 유동파라핀4. Liquid paraffin 15.015.0 5. 베타글루칸5. Beta Glucan 7.07.0 6. 카보머6. Carbomer 0.10.1 7. 세사몰 유도체7. Sesamol Derivatives 적량Quantity 8. 카프릴릭 카프릭 트리글리세라이드8. Caprylic Capric Triglycerides 3.03.0 9. 스쿠알렌9. Squalene 1.01.0 10. 세테아릴 글루코사이드10. Cetearyl Glucoside 1.51.5 11. 소르비탄 스테아레이트11.Sorbitan Stearate 0.40.4 12. 세테아릴 알코올12. Cetearyl Alcohol 1.01.0 13. 방부제13. Preservative 적량Quantity 14. 향14. Incense 적량Quantity 15. 색소15. Coloring 적량Quantity 16. 밀납16. Beeswax 4.04.0

이상에서 알 수 있는 바와 같이, 본 발명에 의해 제공되는 화학식 1의 세사몰 유도체는 세사몰에 직접적으로 아다만탄기를 도입함으로써 항 산화효과가 증대되고 안정성이 향상되어 유해 활성산소에 의하여 손상된 피부의 회복 및 예방에 쓰일 수 있고, 생체막의 노화를 방지할 수 있으며, 불포화지방산 및 그 유도체의 과산화물 생성을 억제할 수 있어 이를 이용한 다른 분야에의 응용이 가능하다. As can be seen from the above, the sesamol derivative of the formula (1) provided by the present invention, by introducing the adamantane group directly into sesamol to increase the antioxidant effect and to improve the stability of the skin damaged by harmful free radicals It can be used for recovery and prevention, can prevent the aging of the biological membrane, can inhibit the production of peroxides of unsaturated fatty acids and derivatives thereof, it is possible to apply to other fields using the same.

Claims (6)

하기 화학식 1로 표현되는 세사몰 유도체.Sesamol derivative represented by the following formula (1). [화학식 1][Formula 1]
Figure 112005040755381-pat00006
Figure 112005040755381-pat00006
세사몰과 아다만탄올을 1 :1.0~1.3의 당량비로 산조건에서 반응시킨 후, 극성용매에서 재결정하여 제조하는, 하기 반응식 1로 표현되는 하기 화학식 1의 세사몰 유도체의 제조방법으로서,As a method for producing sesamol derivative of the general formula (1) represented by the following reaction formula 1, which is prepared by reacting sesamol and adamantanol at an equivalent ratio of 1: 1.0 to 1.3 in acidic conditions, and then recrystallized in a polar solvent. [반응식 1]Scheme 1
Figure 112006079988641-pat00007
Figure 112006079988641-pat00007
[화학식 1][Formula 1]
Figure 112006079988641-pat00008
Figure 112006079988641-pat00008
상기 산은 염산, 질산, 황산, p-톨루엔술폰산, 벤젠술폰산, 아세트산, 트리클로로아세트산 및 트리플로로아세트산으로 이루어진 군에서 선택된 1종 이상이고,  The acid is at least one selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, p-toluenesulfonic acid, benzenesulfonic acid, acetic acid, trichloroacetic acid and trifluoroacetic acid, 상기 극성용매는 메탄올, 에탄올, 이소프로판올, 아세톤, 아세토나이트릴 및 물로 이루어진 군에서 선택된 1종 이상임을 특징으로 하는 세사몰 유도체의 제조방법. The polar solvent is a method for producing sesamol derivatives, characterized in that at least one selected from the group consisting of methanol, ethanol, isopropanol, acetone, acetonitrile and water.
삭제delete 제 2항에 있어서, 상기 세사몰과 아다만티올을 1:1.0~1.3의 당량비로 산조건에서 반응하는데 사용되는 용매로는 디클로로메탄, 테트라히드로퓨란, 초산에틸, 아세토니트릴, 클로로포름, 에틸에테르, 트리클로로 에틸렌, 벤젠, 및 톨루엔으로 이루어진 군에서 선택된 적어도 1종 이상임을 특징으로 하는 세사몰 유도체의 제조방법.  According to claim 2, wherein the solvent used to react the sesamol and adamanthanol in an acid ratio of 1: 1.0 to 1.3 equivalent ratio of dichloromethane, tetrahydrofuran, ethyl acetate, acetonitrile, chloroform, ethyl ether, A method for producing sesamol derivatives, characterized in that at least one selected from the group consisting of trichloroethylene, benzene, and toluene. 삭제delete 상기 제 1항의 세사몰 유도체를 함유하는 것을 특징으로 하는 화장료 조성 물.        A cosmetic composition comprising the sesamol derivative of claim 1.
KR1020050067815A 2005-07-26 2005-07-26 Sesamol derivatives and process for preparing the same KR100682549B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020050067815A KR100682549B1 (en) 2005-07-26 2005-07-26 Sesamol derivatives and process for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050067815A KR100682549B1 (en) 2005-07-26 2005-07-26 Sesamol derivatives and process for preparing the same

Publications (2)

Publication Number Publication Date
KR20070013482A KR20070013482A (en) 2007-01-31
KR100682549B1 true KR100682549B1 (en) 2007-02-15

Family

ID=38013177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020050067815A KR100682549B1 (en) 2005-07-26 2005-07-26 Sesamol derivatives and process for preparing the same

Country Status (1)

Country Link
KR (1) KR100682549B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100841592B1 (en) * 2007-04-16 2008-06-26 한양대학교 산학협력단 Bezodiazole derivatives and process for preparing them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968234A (en) * 1975-03-05 1976-07-06 The United States Of America As Represented By The Secretary Of Agriculture Cinnamyl-sesamol derivatives as insect chemosterilants
EP0776885A1 (en) 1995-12-01 1997-06-04 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Diaromatic compounds with an adamantyl group in the ortho position, pharmaceutical and cosmetic compositions containing them and uses
JP2004131461A (en) 2002-08-12 2004-04-30 Idemitsu Petrochem Co Ltd Adamantane derivative and method for producing the same
US6828446B2 (en) 2001-12-21 2004-12-07 Pharmacia Corporation Aromatic thioether liver X-receptor modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968234A (en) * 1975-03-05 1976-07-06 The United States Of America As Represented By The Secretary Of Agriculture Cinnamyl-sesamol derivatives as insect chemosterilants
EP0776885A1 (en) 1995-12-01 1997-06-04 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Diaromatic compounds with an adamantyl group in the ortho position, pharmaceutical and cosmetic compositions containing them and uses
US6828446B2 (en) 2001-12-21 2004-12-07 Pharmacia Corporation Aromatic thioether liver X-receptor modulators
JP2004131461A (en) 2002-08-12 2004-04-30 Idemitsu Petrochem Co Ltd Adamantane derivative and method for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1020050067815 - 717029

Also Published As

Publication number Publication date
KR20070013482A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
EP1874722B1 (en) Hydroxamic acid derivatives and the preparation method thereof
KR101527280B1 (en) Novel Peptide derivatives from Jellyfish Extract and Composition for Skin External Application Comprising the Same
KR102436291B1 (en) Cosmetic Composition for Skin Whitening Containing Eleutheroside E As Active Ingredient
KR101418986B1 (en) Composition for promoting collagen synthesis and cosmetics comprising the same
KR100682549B1 (en) Sesamol derivatives and process for preparing the same
KR102417302B1 (en) Composition for external application containing a ceramide, a derivative thereof and an extract of Hibisci Cortex
KR101462692B1 (en) Skin whitening cosmetics
KR101050484B1 (en) Skin whitening composition containing lactone compound as an active ingredient
KR101182765B1 (en) Cosmetic Composition Comprising Citrus sunkiSanmul S.Marcov And Zingiber Officinale Roscoe Mixed Extract Having Anti-oxidation and Anti-aging Effects And Manufacturing Method Thereof
KR100851044B1 (en) 3,5-dihydroxy benzamide derivatives having depigmenting activity and the whitening cosmetic composition containing the same
KR101619710B1 (en) Anti-aging Composition for Skin External Application Comprising Liriodendron tulipifera Placenta Culture Extracts
KR101063147B1 (en) Compositions containing ginsenosides Ro (ginsenoside Ro)
KR20040087644A (en) Cosmetic Composition Comprising Pyrus communis L. Extract for Skin Whitening
KR20030057205A (en) Cosmetic compositions for improving appearance using plant extracts containing abscisic acid and derivatives thereof
KR102048982B1 (en) Idebenone derivative compound and cosmetic composition comprising the same
CN110974737A (en) Composition for improving skin comprising pueraria lobata extract or compound derived therefrom
KR101695375B1 (en) Composition for promoting hair growth and restoration comprising new derivatives of pantetheine
KR101786606B1 (en) cosmetics containing tetrandrine
KR20140122012A (en) Cosmetic Composition for Skin Whitening Having Kaempferia Parviflora
KR100787879B1 (en) Tocopherol derivatives containing antioxidant effect and preparation method thereof, and cosmetic composition containing thereof
KR20140122014A (en) Cosmetic Composition for skin Whitening
JP5718700B2 (en) New sesterterpene compound, antibacterial agent and topical skin preparation
KR101056879B1 (en) Sesamol derivatives or salts thereof, preparation method thereof, and external skin composition containing same
KR20110063894A (en) Cosmetic composition containing narirutin
KR20180061663A (en) Composition for skin improvement containing dehydroevodiamine

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130114

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140123

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20150116

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20161228

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee